Recruiting studies: Egfr Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Can
Phase 3 · 49 location(s) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. · NCT07182682 Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946 TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Phase 2 · 1 location(s) · TYK Medicines, Inc · NCT05948813 A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Phase N/A · 3 location(s) · National Cancer Centre, Singapore · NCT06418412 Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT06554613 A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Phase 1 · 1 location(s) · National Cancer Center, China · NCT06362980 To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Lo
Phase 2 · 7 location(s) · OBI Pharma, Inc · NCT05442060 A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464 Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Chinese University of Hong Kong · NCT07379476 A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635 Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT04322890 Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
Phase N/A · 13 location(s) · Swiss Cancer Institute · NCT07617610 Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/Phase 2 · 1 location(s) · China Medical University Hospital · NCT06071013 Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149 ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641 Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Guangzhou Medical Universit · NCT06383728 A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC
Phase 2 · 4 location(s) · Guangdong Association of Clinical Trials · NCT07375316 Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Ef
Phase 2 · 1 location(s) · Xinqiao Hospital of Chongqing · NCT06953843 A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Ce
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07548060 DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Phase 1/Phase 2 · 1 location(s) · Dizal Pharmaceuticals · NCT07070440 JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160 Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation
Phase N/A · 1 location(s) · LifeOS Genomics Corporation · NCT06573073 Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2 · 26 location(s) · Teligene US · NCT05168566 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224 Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT05503667 Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
Phase N/A · 1 location(s) · AstraZeneca · NCT07593248 Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Phase 1/Phase 2 · 1 location(s) · Emory University · NCT04590664 Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Phase 3 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05852990 CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
NA · 1 location(s) · British Columbia Cancer Agency · NCT05257967 Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma
Phase 2 · 3 location(s) · Taipei Medical University Hospital · NCT07624487

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.